Viking Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing innovative treatments for metabolic and endocrine disorders. Its leading drug, VK2809, targets non-alcoholic steatohepatitis and NAFLD with a novel approach, aiming for efficacy and safety. Viking is also advancing VK5211 for hip fracture recovery, VK0612 for type 2 diabetes, VK2735 for metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diverse pipeline aimed at addressing significant unmet medical needs.
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble…
FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are…
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the lithium giant exploded to $145.38. This morning, it’s up another $4.15 and…
The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over…
Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the…
High short interest can help investors identify potential high risks. And, it can also be a sign of a possible short squeeze situation – especially if the stock in question has been…
A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of Novo Nordisk’s (NYSE:NVO | NVO Price Prediction) Ozempic and Wegovy. These injectable…
